Noteworthy, HMGB1 elevated expression in breast cancer is associated with a poorer response, though it also predicts greater benefit from CDK4/6 inhibitors, establishing HMGB1 not only as a resistance target but also as a predictive biomarker [244]. This evidence concerns the gene CDK4 and breast carcinoma.